While not a treatment for ABPA, CFTR modulator therapies have been proposed to have an impact on decreasing ABPA exacerbations due to their disease-modifying effect on other acquired CFTR dysfunction diseases such as COPD and asthma [143]. Here, CFTR is linked to chronic obstructive pulmonary disease.